NeuBase Therapeutics (NASDAQ:NBSE) Sees Significant Decline in Short Interest

NeuBase Therapeutics (NASDAQ:NBSE) was the target of a large decline in short interest in September. As of September 30th, there was short interest totalling 133,700 shares, a decline of 40.2% from the August 30th total of 223,400 shares. Currently, 1.2% of the shares of the stock are sold short. Based on an average daily trading volume, of 159,300 shares, the days-to-cover ratio is currently 0.8 days.

NeuBase Therapeutics stock traded up $0.22 on Friday, reaching $4.72. The company’s stock had a trading volume of 36,691 shares, compared to its average volume of 86,837. NeuBase Therapeutics has a twelve month low of $1.60 and a twelve month high of $6.95.

NeuBase Therapeutics (NASDAQ:NBSE) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.40) EPS for the quarter.

NBSE has been the topic of several recent analyst reports. ValuEngine lowered NeuBase Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, October 5th. BTIG Research initiated coverage on NeuBase Therapeutics in a research note on Tuesday, September 24th. They issued a “buy” rating and a $15.00 price target on the stock.

About NeuBase Therapeutics

NeuBase Therapeutics, Inc, a biotechnology company, engages in the development of various antisense therapies to address genetic diseases in the United States. The company offers gene silencing therapies, including the proprietary PATrOL platform, a peptide-nucleic acid antisense oligonucleotide for genetic diseases caused by mutant proteins, including the Huntington's disease and myotonic dystrophy, as well as various other genetic disorders.

See Also: Tariff

Receive News & Ratings for NeuBase Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuBase Therapeutics and related companies with's FREE daily email newsletter.